GLP-1 Receptor Agonists Market Gains Momentum as Weight-Loss Drugs Redefine Diabetes and Heart Care - Says Strategic Market Research

News provided by

Jun 17, 2026, 10:01 ET

Global GLP-1 Receptor Agonists Market to grow from USD 18.4 billion in 2024 to USD 41.5 billion by 2030 as diabetes treatment, obesity care, cardiovascular risk reduction, oral drug innovation, and payer access reshape metabolic therapeutics

SAMBALPUR, India, June 17, 2026 /PRNewswire/ -- The GLP-1 Receptor Agonists Market is gaining strong momentum as diabetes care, obesity treatment, cardiovascular-risk management, and chronic metabolic health increasingly move into the same therapeutic conversation.

According to Strategic Market Research, the Global GLP-1 Receptor Agonists Market was valued at USD 18.4 billion in 2024 and is projected to reach USD 41.5 billion by 2030, expanding at a CAGR of 12.3% during the forecast period.

The market is no longer being driven only by glucose control in Type 2 diabetes. GLP-1 receptor agonists are now becoming one of the most important therapeutic platforms in obesity and cardiometabolic disease. Their role has expanded from specialist endocrinology use into broader weight management, primary care, cardiology, sleep-related metabolic complications, telehealth prescribing, and long-term chronic disease management.

The growth story is being shaped by a large and persistent disease burden. Global obesity and diabetes prevalence continue to increase, creating demand for therapies that can address more than one metabolic risk factor at a time. GLP-1 therapies are benefiting from this shift because they sit at the intersection of blood glucose control, appetite regulation, weight loss, cardiovascular risk management, and patient-centered chronic care.

As per Strategic Market Research, GLP-1 receptor agonists are increasingly being evaluated not only as pharmaceutical products but as long-term health-system assets. Physicians, insurers, pharmacy benefit managers, governments, and employers are assessing these therapies through a wider lens that includes clinical outcomes, adherence, affordability, supply continuity, reimbursement rules, and potential reduction in downstream obesity- and diabetes-related complications.

Injectables Continue to Lead, But Oral GLP-1 Drugs Define the Next Adoption Layer

Injectable GLP-1 receptor agonists account for 82.0% of global revenue in 2024, representing approximately USD 15.1 billion. Their leadership is supported by established clinical use, once-weekly dosing, stronger specialist familiarity, and broad adoption across Type 2 diabetes and obesity treatment pathways.

The injectable segment remains the commercial backbone of the market because leading GLP-1 brands are already integrated into physician prescribing behavior and pharmacy distribution systems. Long-acting injectables have also helped improve convenience compared with earlier daily-injection regimens, making them more acceptable for chronic disease management.

Oral GLP-1 receptor agonists, valued at approximately USD 3.3 billion in 2024, are expected to become one of the most strategically important growth areas through 2030. Oral options can reduce injection hesitation, support earlier patient initiation, and help move GLP-1 therapy further into primary care and mass-market chronic disease treatment.

Buy now or Order the Full Report: https://www.strategicmarketresearch.com/buy-now/glp-1-receptor-agonists-market

Type 2 Diabetes Anchors Revenue, While Obesity Reshapes Future Demand

Type 2 diabetes mellitus remains the largest indication, accounting for 68.0% of global GLP-1 receptor agonist revenue in 2024, equivalent to approximately USD 12.5 billion. This segment provides the market with a stable chronic-care foundation because diabetes treatment is long-term, prescription-driven, and supported by established clinical monitoring.

Obesity and weight management generated approximately USD 5.9 billion in 2024 and is becoming the fastest-expanding demand pool. This shift is commercially important because obesity treatment dramatically increases the addressable patient population beyond traditional diabetes care.

The approval momentum around obesity and related cardiometabolic indications has changed how buyers view the class. GLP-1 therapies are increasingly being positioned as chronic metabolic treatments rather than short-term weight-loss interventions. This has implications for manufacturing scale, payer budgets, pharmacy access, patient persistence, and long-term brand competition.

North America Leads Market Value as Payer and Access Decisions Shape Adoption

North America holds the largest share of the global GLP-1 Receptor Agonists Market, accounting for 70.0% of revenue in 2024, equivalent to approximately USD 12.9 billion. The United States remains the most important value market because of high obesity prevalence, strong branded-drug uptake, advanced specialist access, and faster adoption of premium metabolic therapies.

The U.S. GLP-1 receptor agonists market is projected to reach approximately USD 24.4 billion by 2030, expanding at a CAGR of 11.2%. Growth is supported by widening use across diabetes and obesity, stronger clinical awareness of cardiometabolic risk, and continued demand for next-generation injectable and oral therapies.

Europe holds a 12.0% share, valued at approximately USD 2.2 billion in 2024, and is projected to reach USD 3.9 billion by 2030. European growth is expected to remain closely tied to reimbursement policy, national health-technology assessments, prescribing eligibility, and payer willingness to support obesity pharmacotherapy at scale.

Asia Pacific is the fastest-growing region, expanding at a CAGR of 15.3% from approximately USD 0.37 billion in 2024 to USD 0.86 billion by 2030. The region's growth is being supported by rising diabetes prevalence, increasing obesity rates, expanding private healthcare access, urban lifestyle shifts, and stronger demand for premium metabolic treatments across China, India, Japan, South Korea, and Southeast Asia.

Request Sample: https://www.strategicmarketresearch.com/request-sample/glp-1-receptor-agonists-market

India Is Emerging as a High-Potential GLP-1 Access Market

India is becoming a closely watched market for GLP-1 receptor agonists because of its large diabetes burden, rising obesity prevalence, and expanding branded and generic pharmaceutical ecosystem. Recent launches of GLP-1-based weight-loss and diabetes therapies have brought global competition into a market where affordability will play a decisive role.

The Indian market highlights a wider global issue: demand is strong, but access depends on price, prescribing infrastructure, patient affordability, and competition from lower-cost alternatives. As more GLP-1 products enter emerging markets, the commercial battle is expected to shift from brand awareness alone toward delivery format, dose flexibility, cost reduction, and long-term treatment persistence.

Retail Pharmacies Lead Distribution as GLP-1 Use Becomes Chronic and Refillable

Retail pharmacies and drug stores lead distribution with a 45.0% share in 2024, equal to approximately USD 8.3 billion. Their dominance reflects the chronic prescription-refill nature of GLP-1 therapy and the importance of pharmacy access in long-term disease management.

Hospital pharmacies generated approximately USD 6.4 billion in 2024, supported by therapy initiation, specialist-led prescribing, and treatment of patients with complex metabolic or cardiovascular risk profiles.

Online pharmacies, valued at approximately USD 3.7 billion in 2024, are expected to grow rapidly as telehealth platforms, digital obesity clinics, recurring prescription models, and home-delivery services expand. This channel is becoming especially relevant for patients seeking convenience, privacy, and continuous refill support.

Competitive Landscape Moves Toward Outcomes, Capacity, and Access

The GLP-1 Receptor Agonists Market includes major pharmaceutical and biotechnology companies such as Novo Nordisk, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Zealand Pharma, Amgen, and Innovent Biologics.

Competition is increasingly focused on long-acting injectables, oral GLP-1 drugs, dual and triple agonists, cardiovascular and metabolic outcome data, obesity label expansion, manufacturing capacity, supply security, and payer access. Companies that can combine clinical differentiation with scalable production and stronger affordability strategies are expected to gain stronger positioning through 2030.

The next phase of the market will not be determined only by prescription demand. It will also depend on how effectively manufacturers and healthcare systems manage cost exposure, insurance coverage, long-term adherence, supply shortages, and patient eligibility criteria.

Outlook Through 2030

The GLP-1 Receptor Agonists Market is expected to maintain strong growth as obesity and diabetes care become more integrated within cardiometabolic disease management. The projected increase from USD 18.4 billion in 2024 to USD 41.5 billion by 2030 reflects a wider transformation in pharmaceutical demand.

GLP-1 receptor agonists are no longer viewed only as diabetes drugs. They are becoming a central therapeutic platform for obesity-led metabolic care, chronic disease prevention, cardiovascular-risk reduction, and next-generation endocrinology treatment.

Manufacturers capable of delivering differentiated clinical profiles, scalable supply, oral and injectable options, payer-aligned access models, and strong real-world evidence are expected to benefit as GLP-1 therapies move deeper into mainstream healthcare systems.

Related Reports

About Strategic Market Research

Strategic Market Research facilitates organizations globally in taking pivotal business decisions by furnishing syndicated and customized research reports that are highly precise in terms of market numbers. We believe every firm, whether a startup in the introduction stage of the product life cycle or an established company in the growth stage, requires market research services to streamline its key business blueprint.

It may be related to product launch, go-to-market strategies, competitive analysis, or new geographical penetration and expansion.

Contact
Sunil Kumar
Strategic Market Research LLP
92, An Guha Lane, Arya Samaj Gali
Sambalpur, Odisha - 768001
India
Phone: +91-826-083-6500
Email: [email protected]
Website: https://www.strategicmarketresearch.com/

SOURCE Strategic Market Research LLP